Malignant glioma, the most common primary brain tumor, is generally incurable. Although phosphatidylinositol-3-kinase (PI3K) signaling features prominently in glioma, inhibitors generally block proliferation rather than induce apoptosis. Starting with an inhibitor of both lipid and protein kinases that induced prominent apoptosis and that failed early clinical development because of its broad target profile and overall toxicity, we identified protein kinase targets, the blockade of which showed selective synthetic lethality when combined with PI3K inhibitors. Prioritizing protein kinase targets for which there are clinical inhibitors, we demonstrate that cyclin-dependent kinase (CDK)1/2 inhibitors, siRNAs against CDK1/2, and the clinical CDK1/2 inhibitor roscovitine all cooperated with the PI3K inhibitor PIK-90, blocking the antiapoptotic protein Survivin and driving cell death. In addition, overexpression of CDKs partially blocked some of the apoptosis caused by PIK-75. Roscovitine and PIK-90, in combination, were well tolerated in vivo and acted in a synthetic-lethal manner to induce apoptosis in human glioblastoma xenografts. We also tested clinical Akt and CDK inhibitors, demonstrating induction of apoptosis in vitro and providing a preclinical rationale to test this combination therapy in patients.
G
liomas are the most common primary brain tumors. Glioblastoma multiforme represents the most frequently occurring, highest grade, and most lethal glioma. Amplification of the epidermal growth factor receptor (EGFR) occurs in 40% of astrocytomas and correlates with advanced disease (1, 2) . EGFR signals, in part, through the lipid kinase phosphatidylinositol-3′-kinase (PI3K). Activation of PI3K in glioma also occurs independently of upstream EGFR, through gain-of-function mutations in the structural gene for PI3Kα (PIK3CA) and by loss of phosphatase and tensin homolog (PTEN), a lipid phosphatase and negative regulator of PI3K signaling (3) .
Given the prominence of signaling through EGFR and PI3K in glioma, small-molecule inhibitors of these pathways have tremendous potential as therapeutics. To date, clinical compounds directed against this axis have been tested against EGFR and, to a more limited extent, against mammalian target of rapamycin (mTOR), a kinase that signals downstream of PI3K (4) . Clinical responses to these agents in glioma have been disappointing, likely, in part, because these therapies are primarily cytostatic rather than apoptotic. In preclinical systems, whereas inhibitors of PI3K effectively block survival signaling by Akt, inhibitors of PI3K alone and in combination with inhibitors of EGFR and of the downstream kinase mTOR failed to induce cell death in vitro or in vivo (5, 6) .
Our knowledge of the PI3K signaling pathway stems in large part from the development of inhibitors that are either panselective or that block specific isoforms within the PI3K family. In screening isoform-selective inhibitors of PI3K, including chemotypes representative of most pharmaceutical drugs entering clinical trials (5, 7), we identified the imidazopyridine inhibitor, PIK-75, as uniquely able to induce apoptosis rather than growth arrest in glioma. Lacking stability in solution and in vivo (8, 9) , the broad target profile and overall toxicity of PIK-75 precluded clinical development. We hypothesized that the efficacy of PIK-75 in inducing apoptosis resulted from a synthetic-lethal interaction between inhibition of PI3K and inhibition of one or more protein kinase targets of PIK-75.
Results

PI3K Inhibitor PIK-75 Induces Apoptosis in Glioma.
We screened six glioma cell lines using a panel of PI3K inhibitors including the PI3Kα-specific compound PIK-90 (Bayer) and the PI3K/mTOR inhibitors PI-103 (Piramed) and LY294002 (Lilly). In each cell line, flow cytometric analyses demonstrated cell cycle arrest with no appreciable apoptosis (Fig. 1A) . In testing additional PI3K inhibitors, we demonstrated that the Piramed p110α/δ inhibitor PIK-75 arrested cells and induced apoptosis (Fig. 1A and Fig. S1A ). Like PIK-90, PI-103, and LY294002, PIK-75 could block phosphorylation of Akt (Fig. 1B and Fig. S1B ). The PTEN wild type (WT) cell line LN229 showed increased levels of apoptosis in comparison with the PTEN mutant (MT) line U87, using doses of PIK-75 that led to equivalent reductions in p-Akt (Fig. 1C and Fig. S1 A and B) . In comparing biochemical activity of LY294002 with PIK-75, LY294002 more potently blocked both pAkt and the mTOR target p-rpS6 (Fig. S1B) , and yet LY294002, in contrast to PIK-75, was unable to promote apoptosis.
Apoptosis Induced by PIK-75 Requires Inhibition of PI3K and Is
Mitochondrial-Dependent. Data in Fig. 1 A and B demonstrated that PIK-75 was unique among PI3K inhibitors in inducing apoptosis, suggesting an off-target effect. In contrast, however, data in Fig. 1C demonstrated that the degree of apoptosis induced in response to PIK-75 varied as a function of PTEN status, suggesting that apoptosis induced by PIK-75 resulted, at least in part, from PI3K inhibition.
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WT LN229 cells stably transduced with Akt-ER (11) . Upon addition of the estrogen receptor (ER) agonist 4-hydroxytamoxifen (4-HT), Akt-ER protein was phosphorylated and activated ( Fig. S2A) . Apoptosis in response to PIK-75 was largely attenuated, whereas G 2 M arrest remained unchanged (Fig. S2B) . In addition, an Akt1/2 inhibitor, which alone did not induce apoptosis, was able to override the effects of increased PI3K signaling in U87 PTEN MT cells, restoring apoptosis in response to PIK-75 (Fig. S2C) . Collectively, these experiments demonstrate that apoptosis (but not arrest at G 2 M) required blockade of the PI3K pathway.
To further characterize apoptosis induced by PIK-75, we examined mouse embryonic fibroblasts (MEFs) deficient in the apoptotic effector Bax (12) . Wild-type (WT) MEFs were sensitive to apoptosis induced by PIK-75, whereas BAX −/− MEFs were resistant (Fig. S3 A and B) . In LN229 glioma cells, knocking down Bax with siRNA also increased resistance to PIK-75 ( Fig. 2  D and E) . Because Bax regulates cell death exclusively through the mitochondrial apoptotic pathway (12, 13) , and loss of Bax blocks cell death induced by PIK75, we conclude that apoptosis initiated by PIK-75 proceeds through a mitochondrial-dependent pathway that requires Bax.
Inhibition of Cyclin-Dependent Kinases and PI3K Induces Synthetic Lethality in Glioma. PIK-75 was unique among a group of lipid kinase inhibitors screened previously in its ability to block both lipid and serine-threonine kinases (7) . We, therefore, reasoned that inhibition of PI3K in combination with inhibition of one or more serine-threonine kinases might uncover a synthetic-lethal combination of lipid and protein kinases, the inhibition of which results in apoptosis. Using SelectScreen Profiling (Invitrogen), we identified 21 kinases that were inhibited over 95% in response to PIK-75 (Table S1) .
From this list of serine-threonine kinases, we tested the cyclindependent kinases 1 and 2 (CDK1 and CDK2) because these were strongly inhibited by PIK-75, had well-described roles in regulating the G 2 M transition, and inhibitors of these kinases are now in clinical trials (14, 15) . Because G 2 arrest was unique to PIK-75, blockade of CDK1 and/or CDK2 could conceivably contribute to the abilities of PIK-75 to induce apoptosis over other G 1 -arresting PI3K inhibitors. PIK-75 also induced p-Erk (Fig. 1B and Fig. S4 A and B) . We, therefore, asked whether combination therapy using inhibitors of PI3Kα with inhibitors of CDK1 and/or CDK2 could induce apoptosis, with accompanying biomarkers demonstrating G 2 arrest and induction of p-Erk.
We treated LN229 PTEN WT cells with small-molecule inhibitors of CDK1 [3-(2- 
Flow cytometric analysis at 24 h showed that both inhibitors induced arrest at G 2 M (Fig. 3A) , and the CDK2 inhibitor demonstrated a dose-dependent increase in p-Erk by immunoblot (Fig. 3B) . Combining the CDK1 inhibitor with the PI3Kα inhibitor PIK-90 did not result in appreciable apoptosis (Fig. 3C ). Combining the CDK2 inhibitor with PIK-90 did demonstrate an increase in apoptosis in comparison with monotherapy. Levels of apoptosis in response to combination therapy were much lower than those observed using PIK-75 ( Fig. 3D ) and were limited to LN229 PTEN WT , with no significant apoptosis seen in PTEN MT cell lines U87 and U373 (Fig. S1 C and D) over monotherapy. These data suggest that blockade of CDK2 cooperates with inhibition of PI3K to drive apoptosis, whereas blockade of CDK1 does not.
To achieve higher selectivity, and to assess whether blockade of CDK1 could further enhance apoptosis observed in response to dual blockade of CDK2 and PI3Kα, we combined siRNAs against CDK1 and CDK2 with small-molecule inhibition of PI3K. Whereas combining PIK-90 with siRNA against CDK1 or CDK2 did not induce appreciable cell death, combining PIK-90 with siRNA against both CDK1 and CDK2 clearly induced apoptosis (Fig. 3E ). These data suggest that CDK1, CDK2, and PI3K cooperate to induce therapeutic resistance in glioma and that combined blockade of these three targets, in part, underlies the ability of PIK-75 to induce apoptosis.
To further clarify the relative contribution of CDK1 versus CDK2 in the synthetic-lethal relationship, LN229 cells were stably transduced with retroviral vectors expressing CDK1, CDK2, or both and treated with PIK-75. Apoptosis was assessed by PARP (poly ADP-ribose polymerase) cleavage and annexin V flow cytometry. Whereas apoptosis induced by PIK-75 was affected modestly by overexpression of CDK1, apoptosis was clearly reduced in cells overexpressing CDK2 and attenuated further in response to overexpression of both CDK1 and CDK2 ( Fig. 3F and Fig. S5 ). We conclude that overexpression of these CDKs drives resistance to PIK-75 and that CDK2 overexpression more potently rescues cells from PIK-75-induced cell death compared with CDK1. Collectively, these data support the importance of CDKs as proapoptotic targets of PIK-75.
Inhibitors of CDK1/2 Cooperate with an Inhibitor of PI3K to DownRegulate Survivin, Resulting in Apoptosis. Roscovitine, a kinase inhibitor with potent activity against CDK1 and CDK2, is currently in trials for treatment of solid tumors (16) (17) (18) . Like PIK-75, roscovitine induced p-Erk (Fig. S4C) . We treated LN229 glioma cells with roscovitine alone and in combination with PIK-90. Combination treatment induced apoptosis, as demonstrated by flow cytometric analysis of sub-G 1 fraction and by immunoblot for cleaved PARP (Fig. 4 A and B) . We validated this result in PTEN WT GBM43 cells cultured from a primary glioma xenograft (19) . Again, incubation of GBM43 cells with PIK-90 and roscovitine yielded higher levels of apoptosis than either agent alone (Fig. 4C) . In contrast, combination therapy using roscovitine and PIK-90 in PTEN MT GBM14 primary cells (Fig. 4D) and PTEN MT glioma cell lines U87 and U373 (Fig. S6) showed a trend toward increased apoptosis, but was not statistically significant, compared with monotherapy. When PTEN WT breast cancer lines MDAMB231 and T47D and PTEN MT breast cancer lines BT549 and SUM149 were treated with roscovitine and PIK-90, all but the T47D line showed significant increases in apoptosis with combination therapy over PIK-90 monotherapy, albeit not over roscovitine monotherapy (Fig. S6) . Collectively, these data suggest the syntheticlethal effect of PI3K and CDK inhibition is limited to PTEN WT glioma cells.
Roscovitine has been shown to reduce levels of the antiapoptotic protein Survivin (20) . To gain insight into mechanism, we investigated levels of Survivin protein in response to roscovitine and PIK-90. siRNA knockdown of Survivin induced apoptosis in LN229 glioma cells (Fig. 4E) . Roscovitine treatment, both alone and in combination with PIK-90, led to reduced levels of Survivin by immunoblot (Fig. 4F) . Overexpressing Survivin in LN229 cells rescued them from the apoptotic effects of combination therapy (Fig. 4F) , suggesting that inhibitors of PI3K and CDK1/2 induce apoptosis in glioma because of a synthetic-lethal interaction leading to blockade of Survivin. (Fig. 5A) . Roscovitine was less effective than PIK-90 in blocking proliferation (levels of Ki-67), whereas combination therapy showed essentially additive antiproliferative effects (Fig. 5B) . Neither agent as monotherapy induced appreciable apoptosis (cleaved caspase 3).
Because GBM43 is fast-growing, tumors in the control group reached intolerable sizes and, at the time of sacrifice, necessitated by size of control tumors and required by our Institutional Animal Care and Use Committee (IACUC) protocol, no clear regression was observed. Nevertheless, roscovitine and PIK-90 led to combinatorial efficacy in driving apoptosis in vivo, with 7.8% of tumor cells staining positively for cleaved caspase 3, compared with 0.6% for tumors treated with roscovitine single agent and 1.6% for tumors treated with PIK-90 as monotherapy. The treatments were well tolerated, with no overt signs of toxicity measured during the trial or at necropsy. Collectively, these experiments suggest that combined inhibition of PI3K, CDK1, and CDK2 can convert a cytostatic therapy into an apoptotic one in malignant glioma, offering a therapeutic rationale translatable to patients with glioma.
MK-2206 is an orally active allosteric Akt inhibitor in clinical trials (21) . MK-7965 is an inhibitor of CDK1 and -2 (as well as CDK5 and -9) that is also under clinical evaluation (22) . In LN229 glioma cells, MK-2206 effectively inhibited Akt (Fig.  S7A) . MK-7965 led to decreases in p-Rb and increases in p-Erk levels (Fig. S7B) . Combination therapy resulted in increased apoptosis compared with either monotherapy arm ( Fig. S7 C and  D) . These data show that inhibiting the PI3K pathway at the level of Akt in combination with this CDK inhibitor would also lead to synthetic lethality in glioma and offers a combination of agents readily translatable to patients.
Discussion
If successful cancer therapies need to target multiple kinases, is it reasonable to discard polyspecific compounds that fail preclinically or clinically because of toxicity? Among such compounds, if one can distinguish targets required for synthetic-lethal interactions specific to tumor cells, from those that contribute nonspecifically to toxicity, can new compounds or combinations be identified that retain efficacy in the setting of an improved toxicity profile? In screening a broad range of PI3K inhibitors, including chemotypes representative of most drugs currently in clinical development, we identified PIK-75 as an inhibitor of PI3Kα that potently induced apoptosis in glioma. However, because of both toxicity and poor drug-like properties, PIK-75 was unsuitable for clinical use in cancer therapy. Using the concept that increased selectivity should correlate with decreased toxicity, we reasoned that inhibition of a select group of PIK-75 targets in combination with inhibition of PI3K might represent a synthetic-lethal approach, inducing apoptosis while retaining a tolerable toxicity profile. We first demonstrated that inhibition of PI3K contributed to apoptosis induced by PIK-75. Next, using a cell-free assay, we identified all annotated kinase targets of PIK-75 and subsequently identified CDK1 and CDK2 as targets critical to the ability of PIK-75 to induce apoptosis in glioma.
Using a PI3Kα-specific inhibitor in combination with a clinical inhibitor of CDK1 and CDK2, we recapitulated the apoptotic effects of the parental compound, developing a combination therapy that showed reduced toxicity, and that induced apoptosis in vivo in murine xenografts. We then extended these data using clinical inhibitors of Akt and CDKs, providing a preclinical rationale for translating this therapy to patients. Although residual tumors from our in vivo experiments clearly showed apoptosis (increased caspase cleavage compared with monotherapy controls), we did not observe frank regression, an observation that may bear on translational relevance.
Cell cycle deregulation is a hallmark of many cancers, and CDK inhibitors have been developed and screened as anticancer agents. A number of recently developed CDK inhibitors like roscovitine show promise in clinical trials (23) . A major challenge in designing such trials is to ensure that a therapeutic response limited to a subset of patients is not overlooked. In this regard, it is clear that the synthetic-lethal approach observed here is most robust in gliomas that are wild type for PTEN, an observation that should be considered, should this combination of agents be moved forward clinically. We also demonstrate that inhibition of Akt could potentiate the apoptotic effect in PTEN MT glioma cells, suggesting that very high levels of Akt might be abrogating the synthetic-lethal effects in PTEN MT glioma and breast cancers.
Current clinical trials are testing PI3K and CDK inhibitors with increased specificity and improved drug-like properties, as well as investigating combinatorial interactions with other agents (23, 24) . Our data demonstrate that PI3K and CDK1/2 inhibitors act in a synthetic-lethal manner to induce apoptosis in PTEN WT glioma xenografts in vivo, presenting a clinically translatable therapeutic for patients with glioma with potential for improved outcomes over cytostatic therapies.
Materials and Methods
Cell Lines and Reagents. Human glioma cell lines LN229, U87, U373, SF767, human glioma GBM43 and GBM14 cells, human breast cancer cell lines BT549, MDAMB231, T47D, and BAX-WT, and BAX-KO MEFs were grown in 10% (vol/vol) FBS. Human breast cancer cell line SUM149 was grown in 5% (vol/vol) FBS. PIK-90, PI-103, and PIK-75 were synthesized as described (7) Flow Cytometry. For cell cycle analysis, nuclei were stained with 5 μg/mL propidium iodide containing 125 units/mL RNase and analyzed in a FACS Calibur flow cytometer (Becton Dickinson). DNA histograms were modeled offline using Modfit-LT software (Verity Software). Apoptosis was detected by measurement of sub-G 1 fraction or by flow cytometry for annexin V-FITC according to the protocol of the manufacturer (BioVision). P values of statistical significance were obtained by Student's t test. siRNA Transfection and Retroviral Transduction. For transfections, control siRNA (Santa Cruz Biotechnology) and CDC2 (CDK1) and CDK2 siRNA (Dharmacon) were transfected using Lipofectamine 2000 (Invitrogen) as described previously (25) . To generate retrovirus, we cotransfected the packaging cell line HEK 293T with pMSCV-CDK1 and/or pMSCV-CDK2, along with plasmids expressing gag/pol and VSVg (vesicular stomatitis virus glycoprotein), using Effectene transfection reagent (Qiagen). At 48 h posttransfection, the viral supernatants were filtered and used to infect LN229 cells. Infected cells were selected with 0.5 μg/mL puromycin. The cloning region of human Survivin cDNA was cloned by PCR into the pENTR/D-TOPO plasmid (Invitrogen) and then subcloned by gateway recombination into pLENTI CMV/TO Puro DEST plasmid [Addgene (26) ]. Lentiviral particles were generated in HEK293T cells as described previously (ViraPower protocol; Invitrogen). LN229 cells were transduced and selected for 2 wk with puromycin.
Immunoblotting. Membranes were blotted with p-Akt (Ser473), Akt (pan), p-Erk (Thr202/Tyr204), p-S6 ribosomal protein (Ser235/236), S6 ribosomal protein, p-Rb (Ser807/811), cleaved-PARP (Asp214), BAX, CDK1, CDK2, Survivin (all from Cell Signaling), Erk2 (Santa Cruz), β-tubulin, or GAPDH (Millipore). Bound antibodies were detected with HRP-linked anti-mouse or anti-rabbit IgG (Calbiochem), followed by ECL (Amersham). Cells positive for cleaved caspase 3 were detected as described previously (27) .
Immunohistochemistry. Tumor tissues were fixed in 4% paraformaldehyde (PFA) and 20% sucrose and then embedded in OCT compound as described (28) . Sections of 10-μm thickness were cut and placed on silane-coated slide glasses. Sections were incubated at 4°C overnight with mouse monoclonal anti-Ki-67 (1:1; Zymed) and rabbit polyclonal anti-cleaved caspase 3 antibody (1:200; Cell Signaling) and at room temperature with anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 555 secondary antibodies (1:100, Molecular Probes) for 1 h. Nuclei were labeled with Hoechst. Sections were mounted with Vectashield mounting media and analyzed with a Zeiss 510 LSM confocal microscope. 
